52nd ANNUAL MEETING OF THE SCNP

OSLO, NORWAY
APRIL 12-14, 2011

SCIENTIFIC PROGRAMME
http://scnp.org
 
 TUESDAY, APRIL 12, 2011
10.00- REGISTRATION OPENS

1100-1130 General assembly

1130-12.15  LUNCH

12.30-13.15 PLENARY SESSION

President´s welcome
Ole A. Andreassen (Oslo)

Genetic susceptibility and environmental stressors in psychosis  

Sir Robin M. Murray (London)

13.15-14.45 PLENARY SESSION
Oxytocin; balancing attachment and suspiciousness?
Moderators: Cort A. Pedersen (North-Carolina) & Ole A. Andreassen (Oslo)

Oxytocin – mechanisms of action and psychological effects 

Inga Neumann (Regensburg)

An Oxytocin Treatment Trial in Schizophrenia: Reduction of Social Cognitive

Deficits and Psychotic Symptoms
Cort A. Pedersen (North-Carolina)

Preclinical and Clinical Evidence for Oxytocin's Therapeutic Effects in

Schizophrenia
Kai MacDonald (San Diego)

14.45-15.15  COFFEE BREAK

15.15-16.45 PARALLEL SESSIONS

I. ADHD, are we treating the right patients? 

Moderators: Anne-Liis von Knorring (Uppsala) &Jesper Ekelund (Helsinki)

Epidemiology. Diagnostics, co-morbidity and progress to adulthood.

Pål Zeiner (Oslo)
 
The problems with treating ADHD in substance abuse
Matthías Halldórsson (Reykjavik)

Treatment of ADHD symptoms

Anne-Liis von Knorring (Uppsala)

II. Augmentation strategies in treatment resistant depression

Moderators: Gregers Wegener (Aarhus) & Ulrik F. Malt (Oslo)

Light exposure and sleep-wake cycle based therapies

Timo Partonen (Helsinki)
 Augmentation by combining antidepressant and antipsychotic drugs.
Torgny H. Svensson (Stockholm)

Augmentation of antidepressant treatment – a practical clinical approach

Ulrik F. Malt (Oslo)

16.45-17.00   BREAK

17.00-18.15   PLENARY SESSION

New treatment options in neuropsychiatric disorders
Moderators: Dag Aarsland (Stockholm/Oslo) & Tove Gunnarson (Stockholm)

Antipsychotics for the elderly: how harmful are they?

Dag Aarsland (Stockholm/Oslo)

Alzheimer’s drugs in the next decade

Niels Andreasen (Stockholm)

OSU 6162 shows effect on mental fatigue in clinical trial

Arvid Carlsson (Gothenburg)

19.00-21.00 WELCOME RECEPTION  

WEDNESDAY, APRIL 13, 2011

09.00-9.45  PLENARY SESSION

SCNP 2011 –LECTURE

Moderator: Torgny H. Svensson (Stockholm)

Psychopharmacology and cognition.

Barbara Sahakian (Oxford)

09.45-11.15   PLENARY SESSION

ECNP Educational Symposium – New areas for drug development

Moderators: Jesper Ekelund (Helsinki) & Arvid Carlsson (Gothenburg)

Biomarkers to guide drug development in neuropsychiatric disorders – example

from  Alzheimer’s disease
Kaj Blennow (Gothenburg)

Alteration of emotional processing as a marker of antidepressant action

Mike Browning (Oxford)

New genetics findings in psychiatry – can it facilitate drug development?

David A. Collier (London)

Future applications of molecular imaging in drug development

 Lars Farde (Stockholm)

11.15-11.45  COFFEE BREAK

11.45-13.15   SATELLITE SYMPOSIUM ELI LILLY

Present and future challenges in the long-term management of Schizophrenia

Moderator: Hugo A. Jørgensen (Bergen)

Challenges in the long-term management of schizophrenia.

Sir Robin M. Murray (London)

Removing the roadblocks. How to overcome the barriers to adherence.

Cecilia Brain (Gothenburg)
Olanzapine long-acting injection. A review of clinical data.
Ole Kristian Kleivenes (Lilly Scandinavia)
             
13.15-14.00  LUNCH

14.00-15.30  PLENARY SESSION

Lithium revisited
Moderators: Gregers Wegener (Aarhus) & Anders Svensson (Stockholm)

The history of Lithium treatment

Lars von Knorring (Uppsala)

Preclinical mechanism of action

Vidar M. Steen (Bergen)

Lithium - old and new evidence on its efficacy in bipolar disorder

Rasmus Licht (Aarhus)

15.30-16.00  COFFEE BREAK

16.00-17.15  PLENARY SESSION

SCNP YOUNG SCIENTIST SYMPOSIUM

Moderators: Ole A. Andreassen (Oslo) and Gregers Wegener (Aarhus)

Concomitant NET inhibition enhances the antipsychotic-like effect of quetiapine in

rats and enhances prefrontal dopamine output and cortical NMDA receptor-
mediated transmission
Carl Bjørkolm (Stockholm)

The ghrelin signalling system is involved in the consumption of sweets as wel as of

alcohol
Elisabet Jerlhag (Gothenburg)

Cardiovascular risk factors during second generation antipsychotic treatment are

associated with increased immune markers
Ingrid Dieset (Oslo)
 Serotonin transporter gene polymorphism, childhood trauma and cognition in patients with
psychotic disorders
Monica Aas (Oslo)

A novel cAMP effector mechanism in mood-regulation?

Nico Libenberg (Aarhus)

Acute behavioral stress affects the readily relesable pool of vesicles in

prefontal/frontal cortex
Nicoletta Nava (Aarhus)

17.15-18.45 POSTER SESSION. Refreshments

19.00-  52nd  CONGRESS DINNER. Holmenkollen

THURSDAY, APRIL 14TH, 2011

9.00-9.45     PLENARY SESSION

SCNP Educational Lecture:

Moderator: Ole A. Andreassen (Oslo)

Depression and heart disease – common biology?

Poul Videbech (Aarhus)

09.45-10.30   PLENARY SESSION

SCNP 2011 Frontiers Lecture

Moderator: Torgny H. Svensson (Stockholm)

Emotional processing in depression

Guy Goodwin (Oxford)

10.30-11.00  COFFEE BREAK

11.00-12.30 PLENARY SESSION

Early treatment strategies in schizophrenia– are we there yet?

Moderators: Ingrid Melle (Oslo) & Tove Gunnarsson (Stockholm)

The case for prevention in psychotic disorders

Ingrid Melle (Oslo)

Current treatment strategies in high-risk patients

Shôn Lewis (Manchester)

Stage dependent effect of omega-3 fatty acids in emerging psychosis

Gregor Berger (Zürich)
12.30-13.30 LUNCH

13.30-15.00   PARALLEL SESSIONS

I. Suicide – impulsivity. A recent update

Moderators: Gregers Wegener (Aarhus) & Lil Träskman Bendz (Lund)

New evidence of predictors of suicidality

Lil Träskman Bendz (Lund)

Impulsivity and serotonin neurotransmission: genetic and environmental factors

Espen Walderhaug (Oslo)

SSRI question revisited 

Göran Isacsson (Stockholm)

II. Trends and treatment in addiction

Moderators: Jørgen Bramness (Oslo) & Ole A. Andreassen (Reykjavik)

Mechanisms involved in ethanol´s interaction with the brain reward system

Bo Söderpalm (Gothenburg)

Can the smoking cessation agent varenicline be used for treatment of alcohol
dependence?
Elin Löf (Gothenburg)

Pharmacological treatment for drug craving - getting anywhere?

Jørgen Bramness (Oslo)

15.00-15.15  CONCLUSION OF MEETING

Ole A. Andreassen (Oslo) 
See more info on registration and abstract
submission on our website
http://scnp.org